Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Preston Klassen Sells 31,445 Shares of Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) insider Preston Klassen sold 31,445 shares of Regulus Therapeutics stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $39,620.70. Following the transaction, the insider now directly owns 36,055 shares in the company, valued at $45,429.30. This trade represents a 46.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Regulus Therapeutics Trading Up 3.7 %

Shares of RGLS stock opened at $1.27 on Thursday. Regulus Therapeutics Inc. has a fifty-two week low of $1.08 and a fifty-two week high of $3.79. The stock has a 50 day moving average price of $1.52 and a two-hundred day moving average price of $1.59.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). On average, analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Regulus Therapeutics in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Regulus Therapeutics has an average rating of “Moderate Buy” and an average target price of $10.80.

Institutional Trading of Regulus Therapeutics

Institutional investors have recently modified their holdings of the company. Creative Planning bought a new position in Regulus Therapeutics during the 3rd quarter valued at approximately $26,000. SG Americas Securities LLC purchased a new position in shares of Regulus Therapeutics during the third quarter valued at approximately $33,000. Jane Street Group LLC purchased a new position in shares of Regulus Therapeutics during the third quarter valued at approximately $46,000. JPMorgan Chase & Co. raised its holdings in shares of Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 52,059 shares in the last quarter. Finally, Barclays PLC lifted its stake in Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 62,549 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.